Trial
NCT00198081
Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Indiana University
Collaborators
—
Condition
Pancreas Neoplasms
Intervention
COX-2 Inhibitor 6-8 weeks prior to surgery
Why stopped
Lack of funding and personnel to conduct study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-02-29